Patents Examined by James Rogers
  • Patent number: 9623122
    Abstract: The present invention provides a molecular assembly whose retention time in a target site is adjusted depending on the kind or purpose of a labeling agent or drug encapsulated therein, and a molecular assembly that can suppress the ABC phenomenon and that can be administered more than once within a short span.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: April 18, 2017
    Assignees: SHIMADZU CORPORATION, KYOTO UNIVERSITY
    Inventors: Isao Hara, Eiichi Ozeki, Shunsaku Kimura, Akira Makino
  • Patent number: 9623123
    Abstract: The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 18, 2017
    Assignee: MICHIGAN TECHNOLOGICAL UNIVERSITY
    Inventor: Haiying Liu
  • Patent number: 9612242
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: April 4, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang
  • Patent number: 9603976
    Abstract: Biodegradable coatings for implantable medical devices are disclosed.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: March 28, 2017
    Assignee: ABBOTT CARDIOVASCULAR SYSTEMS, INC.
    Inventor: Stephen Dirk Pacetti
  • Patent number: 9605052
    Abstract: A method for extracting IgY (?-livetin) from yolk is disclosed, which comprises the following steps: (A) providing a buffer solution, a yolk sample, and an inorganic salt solution; (B) diluting the yolk sample with the buffer solution to obtain a mixture, stirring the mixture for a predetermined time, and performing a centrifugation on the mixture to obtain a supernatant; and (C) adding the inorganic salt solution into the supernatant to salt out IgY, wherein a pH value of the buffer solution is in a range from 4.6 to 5.4, a salt concentration of the buffer solution is in a range from 0.05 M to 0.15 M, and a saturation degree of the inorganic salt solution is in a range from 30% to 60%.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: March 28, 2017
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Yu-Chie Wang, Zong-Ming Wang
  • Patent number: 9597402
    Abstract: An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having Cmax to Cmin ratio less than 200 and lag time less than 0.2.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 21, 2017
    Assignee: DURECT CORPORATION
    Inventors: Andrew S. Luk, Gunjan H. Junnarkar, Guohua Chen
  • Patent number: 9598460
    Abstract: Embodiments herein provide methods of purifying monoclonal and polyclonal antibodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: March 21, 2017
    Assignee: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Zihni Basar Bilgicer, Tanyel Kiziltepe Bilgicer, Nathan Joseph Alves, Jonathan Darryl Ashley, Michael William Handlogten
  • Patent number: 9585910
    Abstract: Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 7, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Christopher W. Bielawski, Abdullah Aydogan, Daniel J. Coady
  • Patent number: 9585911
    Abstract: A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: March 7, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg
  • Patent number: 9581597
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: February 28, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang
  • Patent number: 9575065
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: February 21, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang
  • Patent number: 9566246
    Abstract: The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 14, 2017
    Assignee: CHIASMA INC.
    Inventors: Roni Mamluk, Moshe Tzabari, Karen Marom, Paul Salama, Irina Weinstein
  • Patent number: 9561252
    Abstract: A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: February 7, 2017
    Assignee: GLYCOREX TRANSPLANTATION AB
    Inventor: Kurt G. I. Nilsson
  • Patent number: 9556210
    Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: January 31, 2017
    Assignee: SABAG-RFA LTD.
    Inventor: David Segev
  • Patent number: 9556261
    Abstract: The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 31, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Lucia Gnauer, Harald Arno Butterweck, Theresa Bauer, Alfred Weber, Wolfgang Teschner, Hans-Peter Schwarz
  • Patent number: 9554987
    Abstract: The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 31, 2017
    Assignee: ULTRAGENYX PHARMACEUTICAL INC.
    Inventor: Emil Kakkis
  • Patent number: 9533006
    Abstract: Marine coatings including cationic polymers hydrolyzable to nonfouling zwitterionic polymers, coated marine surfaces, and methods for making and using the marine coatings.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: January 3, 2017
    Assignee: University of Washington
    Inventors: Shaoyi Jiang, Xuewei Xu, Yuting Li, Andrew Keefe, Hong Xue, Shengfu Chen
  • Patent number: 9532991
    Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 3, 2017
    Assignees: Shandong Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd
    Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
  • Patent number: 9534014
    Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: January 3, 2017
    Assignee: Signature Therapeutics, Inc.
    Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
  • Patent number: 9522197
    Abstract: The invention relates to nanoparticles comprising a biodegradable polymer, a cyclodextrin or a derivative thereof, and a biologically active molecule. Said nanoparticles can associate large amounts of biologically active molecules, especially of a hydrophobic nature, and release the biologically active molecule providing sustained and constant plasma levels thereof when they are administered orally or through any other mucosa of the organism.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: December 20, 2016
    Assignee: INNOUP FARMA, S.L.
    Inventors: Maite Agüeros Bazo, Hesham H. A. Salman, Juan Manuel Irache Garreta, Miguel Angel Campanero Martínez